E-cigarette or Vaping Product Use-Associated Lung Injury Complicated by Pulmonary Aspergillosis

Since the initial reports regarding the nationwide outbreak of e-cigarette or vaping product use-associated lung injury (EVALI) in August 2019 by the Centers for Disease Control and Prevention, a clear link has been established between EVALI and tetrahydrocannabinol (THC)-containing product use. We...

Descripción completa

Detalles Bibliográficos
Autores principales: Kupelian, Chloe, Kim, Andrew, Vijayan, Vini
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Infectious Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719479/
https://www.ncbi.nlm.nih.gov/pubmed/34987937
http://dx.doi.org/10.7759/cureus.20075
Descripción
Sumario:Since the initial reports regarding the nationwide outbreak of e-cigarette or vaping product use-associated lung injury (EVALI) in August 2019 by the Centers for Disease Control and Prevention, a clear link has been established between EVALI and tetrahydrocannabinol (THC)-containing product use. We report a case of invasive pulmonary aspergillosis (IPA) as a complication of EVALI in an immunocompetent adolescent that resulted in a fatal outcome. We encourage physicians that are considering the diagnosis of EVALI be cognizant of the increased use of THC and other potential contaminants in vaping cartridges. IPA can be a fatal disease and early aggressive treatment is necessary.

Ejemplares similares